Pulmo BioTech Inc. (OTC.BB: PLMO) (FRANKFURT:PBO) has completed the final stages of the experimental work required for Regulatory Approval need to start the Phase I Human Trials. The Phase I Human Trials comes following the completion of the 'Local reaction study' and the 'Binding studies with MCF-7 cells.' The company has now concluded all of the necessary work needed in order to start the Phase I Trials. The company is finalizing the documentation packs before they submit their report to the Regulatory Authority to get permission to start Phase I Human Trials of the company's pulmonary imaging agent, PulmoBind.
MicroCap Insider is a web-based financial portal that publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors. Sign Up for our Free Stock Newsletter
About Pulmo BioTech Inc.
Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stockholders.
Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website
About Us
MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.
Please click here to read the full disclaimer
